Clinical Trial: Randomized, Open-label, Single-dose, Two-period, Double- crossover Bioequivalence Study of Tofacitinib Citrate Extended-release Tablets in Healthy Subjects Under Fasting and Postprandial Conditions (China)

Posted On: 2026-09-18

China, Sept. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Randomized, Open-label, Single-dose, Two-period, Double- crossover Bioequivalence Study of Tofacitinib Citrate Extended-release Tablets in Healthy Subjects Under Fasting and Postprandial Conditions'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132803

Registration Time: 2026/09/18

Type: Interventional study

Primary Sponsor: Zhejiang Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=330974

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Randomized, Open-label, Single-dose, Two-period, Double- crossover Bioequivalence Study of Tofacitinib Citrate Extended-release Tablets in Healthy Subjects Under Fasting and Postprandial Conditions (China)